New Post

Hey all,

Happy Tuesday! The 23andMe bankruptcy is weird to me as founder Anne Wojcicki and others offered to buy the company previously. If someone understands the advantage of a bankruptcy over a sale, please let me know. Enjoy the rundown!

Jacob Brody (Co-Founder & CEO, ZorroRX)

(Modern Healthcare) Dozens of Health Systems Reject $2.8B BCBSA Antitrust Deal

More than 100 healthcare providers have filed new antitrust lawsuits against the Blue Cross Blue Shield Association (BCBSA) and its 33 affiliates, alleging they conspired to suppress competition and lower hospital reimbursement rates. Major health systems, including the University of Pennsylvania and CommonSpirit Health, opted out of a $2.8 billion settlement approved in December, arguing that previous legal agreements failed to introduce meaningful market reforms. The lawsuits claim BCBSA continues to divide territories and limit competition, violating the Sherman Antitrust Act, and seek damages along with future protections. Full Article

(STAT News) 23andMe Files for Bankruptcy as Anne Wojcicki Resigns, Plans to Buy It Back

Genetic testing company 23andMe has filed for bankruptcy amid declining sales, regulatory hurdles, and data privacy concerns, prompting CEO Anne Wojcicki to step down. However, Wojcicki is now preparing a bid to reacquire the company through the bankruptcy process, signaling her belief in its long-term potential despite recent struggles. Her latest effort comes after the board previously rejected her buyout attempts, making it unclear whether she will succeed this time. Full Article

(Employer Coverage) Women’s Out-of-Pocket Drug Costs

A recent GoodRx study found that women spent nearly 30% more out-of-pocket on prescriptions than men in 2024, totaling an additional $8.5 billion. This disparity stems from women’s higher healthcare utilization, a greater burden of chronic conditions, and increased spending on mental health treatments. The cost gap is most pronounced among women aged 18-44, who pay up to 64% more than men in some years. While not a traditional “pink tax,” this financial burden highlights the need for gender-conscious healthcare policies. Full Article